EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Persistent hypoglycemia in patients with liver cancer

Kemal Fariz Kalista iD, Hanum Citra Nur Rahma, Dicky Levenus Tahapary, Saut Horas Nababan, Chynthia Olivia Maurine Jasirwan, Juferdy Kurniawan, Cosmas Rinaldi Adithya Lesmana, Andri Sanityoso Sulaiman, Irsan Hasan, Rino Gani

Endocrinology, Diabetes & Metabolism Case Reports · 01.07.2024 · 2024 (3)

DOI: 10.1530/edm-23-0077 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrinology, Diabetes & Metabolism Case Reports, erschienen am 01.07.2024. Verfasst von Kemal Fariz Kalista und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hepatobiliary, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Faculty of Medicine Universitas Indones…. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypoglycemia is one of the paraneoplastic syndrome manifestations that arise from primary and secondary liver cancer. Hypoglycemia usually presents in the late stage of the disease and indicates a poor prognosis. This case series displays the characteristics profile of patients with primary and secondary liver cancer who are presented with hypoglycemia in a tertiary referral hospital in Indonesia. The study included 41 liver cancer patients who were presented with hypoglycemia. Hepatocellular carcinoma was diagnosed in 51.2% of patients, metastatic liver disease in 14.6% of patients, and undiagnosed liver cancer in 34.1% of patients. The mean age was 47.7 years with male predominance (65.9%). Jaundice was found in 58.5% and hepatomegaly in 70.7% of patients. The mean (± S.D.) initial blood glucose was 42.15 ± 17.11 mg/dL and the Child–Pugh score was 9.93 ± 2.11. Based on imaging, tumor diameter was 12.6 ± 6.9 cm, multiple (61%), and involving both lobes (61%). Treatments for hypoglycemia included oral/enteral feeding, intravenous dextrose, and steroids. No treatment was given for the cancer because all patients were in an advanced stage. The treatment resulted in 41.5% blood glucose being controlled, 56.1% refractory, and 2.4% persistent. Mortality was 70.7% and in average occurred 5.76 ± 4.99 days after hypoglycemia. The mainstay of treatment in these cases is treating the tumor with cytoreduction. However, it was difficult to do cytoreduction because the tumor was already in an advanced stage. Beneficial supportive treatments for maintaining normal blood glucose are frequent meals, dextrose infusion, steroids, and glucagon. Learning points Hypoglycemia in liver cancer occurs due to the failure of the liver to fulfill body glucose demand because the liver parenchyma has been largely replaced by the tumor, in addition to the high production of insulin growth factor (IGF). Hypoglycemia is often caused by islet cell and non-islet cell tumors, with a higher occurrence in non-islet cell tumors due to paraneoplastic syndrome and the high metabolic requirements of the tumor. The mainstay of NICTH treatment is treating the tumor with cytoreduction. However, in an advanced stage, cytoreduction therapy is often challenging to conduct. Beneficial supportive treatments for controlling blood glucose are frequent meals, dextrose infusion, and the injection of steroids and glucagon. Steroids play a beneficial role in the treatment of persistent hypoglycemia in hepatocellular carcinoma by stimulating gluconeogenesis and increasing lipolysis. Steroids also have roles in the inhibition of peripheral glucose intake, suppression of big IGF-2 production, and modulation of the GH–IGF axis.

Autor:innen und Institutionen

  • Division of Hepatobiliary, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.
  • Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.
  • Division of Endocrinology, Metabolism and Diabetes, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.

ORCID-Profile: Kemal Fariz Kalista

Zitieren

APA

Kalista, K. F., Rahma, H. C. N., Tahapary, D. L., Nababan, S. H., Jasirwan, C. O. M., Kurniawan, J., Lesmana, C. R. A., Sulaiman, A. S., Hasan, I., & Gani, R. (2024). Persistent hypoglycemia in patients with liver cancer. Endocrinology, Diabetes & Metabolism Case Reports, 2024(3). https://doi.org/10.1530/edm-23-0077

Vancouver

Kalista KF, Rahma HCN, Tahapary DL, Nababan SH, Jasirwan COM, Kurniawan J, et al. Persistent hypoglycemia in patients with liver cancer. Endocrinology, Diabetes & Metabolism Case Reports. 2024;2024(3). doi:10.1530/edm-23-0077

BibTeX
@article{Kalista2024,
  author = {Kalista, Kemal Fariz and Rahma, Hanum Citra Nur and Tahapary, Dicky Levenus and Nababan, Saut Horas and Jasirwan, Chynthia Olivia Maurine and Kurniawan, Juferdy and Lesmana, Cosmas Rinaldi Adithya and Sulaiman, Andri Sanityoso and Hasan, Irsan and Gani, Rino},
  title = {Persistent hypoglycemia in patients with liver cancer},
  journal = {Endocrinology, Diabetes & Metabolism Case Reports},
  year = {2024},
  volume = {2024},
  number = {3},
  doi = {10.1530/edm-23-0077}
}
Kostenlos starten →